Cumulative risk of 1-year MACE after LT was analyzed using Kaplan-Meier method. Multivariate logistic regression analysis assessed factors associated with 30-day MACE and Cox proportional hazard models assessed 1-year MACE post-LT. RESULTS: Of 1024 LT recipients (mean age 56.3 ± 9.7 years, 65.9% male, 71.6% white), 322 (31.4%) had at least one MACE within 1

year of LT; most events [238/322 (73.9%)] occurred within the first 30 days of transplant. The most common underlying cause of a 1-year MACE was heart failure [156/322 (48.4%)], followed by atrial fibrillation (40.1%) and stroke (23.9%). Distribution was similar for 30-day events. In multivariate analysis, Selleckchem ABT263 independent predictors of 30-day MACE were older age [Odds ratio (OR): 1.04 (1.02-1.06)] Dinaciclib and higher calculated model for end-stage liver

disease (MELD) score [OR: 1.05 (1.04-1.07)] at transplant, non-Hispanic ethnicity [OR: 2.44 (1.34-4.42)], and prior history of heart failure [OR: 2.3 (1.6-3.4)], isch- emic heart disease [OR: 1.5 (1.09-2.1)], and stroke [OR: 2.4 (1.2-4.8)]. For 1-year MACE, only older age [Hazard Ratio (HR)=1.05 (1.03-1.06)], higher MELD score [HR: 1.04 (1.031.05), non-Hispanic ethnicity (HR: 1.74 (1.15-2.63), and prior history of heart failure [HR=1.9 (1.5-2.4)] and stroke [HR: 1.8 (1.1-2.8)] remained predictive. The models showed moderate discrimination (c-statistic 0.73, 95% CI: 0.69-0.77). CONCLUSIONS: Cardiac complications after liver transplant are common (over 1/3 of patients experience a MACE within 1 year of LT) and the majority of events are related to non-coronary causes. Pre-transplant heart failure, ischemic heart disease and stroke, all modifiable risk factors, substantially increase risk of an early MACE. Future prospective studies aimed at determining whether aggressive risk factor reduction of modifiable factors can decrease non-coronary MACE and improve post-LT outcomes are needed. Disclosures:

The following people have nothing to disclose: Lisa B. VanWagner, Bing Bing Weitner, Tanvi Subramanian, Sarah Uttal, Alfred W. Rademaker, Josh Levitsky, DNA Methyltransferas inhibitor Donald M. Lloyd-Jones, Anton I. Skaro INTRODUCTION: Sphincter of Oddi dysfunction (SOD) in liver transplant (LT) recipients can occur 3-16% of patients, however there is scarce data regarding the specific characteristics, incidence, and long term outcome of this condition. The aim of this analysis was to estimate the incidence and outcome of SOD in a cohort of LT recipients. METHODS: We reviewed 460 ERCP’s performed in LT-patients with duct-to-duct biliary anastomosis at Hospital Clinic, Barcelona from 2003 to 2013. Information was obtained from electronic health records and a prospec-tively collected database. SOD in LT recipients was defined as the presence of cholestasis, elevated liver enzymes, dilated bile duct and absence of alternative diagnosis at ERCP. Patients with SOD underwent a biliary sphincterotomy with adequate drainage of contrast and bile.